Drug intelligence / Profile preview

DE3

Development stage
Unknown
Lead developer
LYS PHARMA
Modality
Small Molecules
Administration
Oral
01

Overview

DE3 is a high-potency omega-3 dietary supplement developed by LYS PHARMA in partnership with the U.S.-based company PRN (Physician Recommended Nutriceuticals). Specifically formulated for the management of dry eye disease, DE3 contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a re-esterified triglyceride (rTG) form. This formulation is designed to enhance absorption and bioavailability compared to standard ethyl ester omega-3 products. DE3 works by modulating the inflammatory response on the ocular surface and improving the quality of the lipid layer of the tear film. Its efficacy is supported by clinical data, including double-blind, placebo-controlled trials (DBDCT), which demonstrate improvements in tear osmolarity and symptomatic relief for patients with dry eyes.

Brand names
DE3DE-3DE 3Dry Eye Omega-3
Other names
디이3DE3 90 capsulesDE-3 90 capsulesDE 3 90 capsulesDE3 270 capsulesDE-3 270 capsulesDE 3 270 capsules
02

Targets

FFAR4 (Free fatty acid receptor 4)COXALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on DE3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DE3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call